NO324452B1 - Anvendelse av tetrahydrolipstatin til fremstilling av medikamenter mot diabetes - Google Patents
Anvendelse av tetrahydrolipstatin til fremstilling av medikamenter mot diabetes Download PDFInfo
- Publication number
- NO324452B1 NO324452B1 NO19993717A NO993717A NO324452B1 NO 324452 B1 NO324452 B1 NO 324452B1 NO 19993717 A NO19993717 A NO 19993717A NO 993717 A NO993717 A NO 993717A NO 324452 B1 NO324452 B1 NO 324452B1
- Authority
- NO
- Norway
- Prior art keywords
- tetrahydrolipstatin
- administered
- use according
- pharmaceutical preparation
- per day
- Prior art date
Links
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title claims description 27
- 229960001243 orlistat Drugs 0.000 title claims description 26
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 3
- 229940127003 anti-diabetic drug Drugs 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 235000012054 meals Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 1
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000007410 oral glucose tolerance test Methods 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3738397P | 1997-02-05 | 1997-02-05 | |
| PCT/EP1998/000468 WO1998034630A1 (en) | 1997-02-05 | 1998-01-29 | Use of gastrointestinal lipase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO993717D0 NO993717D0 (no) | 1999-07-30 |
| NO993717L NO993717L (no) | 1999-10-04 |
| NO324452B1 true NO324452B1 (no) | 2007-10-22 |
Family
ID=21894047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19993717A NO324452B1 (no) | 1997-02-05 | 1999-07-30 | Anvendelse av tetrahydrolipstatin til fremstilling av medikamenter mot diabetes |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6147108A (xx) |
| EP (1) | EP1017408B1 (xx) |
| JP (1) | JP2001509173A (xx) |
| KR (1) | KR100479968B1 (xx) |
| CN (1) | CN1154505C (xx) |
| AR (1) | AR011106A1 (xx) |
| AT (1) | ATE292975T1 (xx) |
| AU (1) | AU740375B2 (xx) |
| BR (1) | BR9807655A (xx) |
| CA (1) | CA2278854C (xx) |
| CZ (1) | CZ295567B6 (xx) |
| DE (1) | DE69829763T2 (xx) |
| DK (1) | DK1017408T3 (xx) |
| ES (1) | ES2239799T3 (xx) |
| HK (1) | HK1025251A1 (xx) |
| HU (1) | HU230834B1 (xx) |
| ID (1) | ID22650A (xx) |
| IL (1) | IL131007A0 (xx) |
| ME (1) | ME00578A (xx) |
| NO (1) | NO324452B1 (xx) |
| NZ (1) | NZ336755A (xx) |
| PL (1) | PL191222B1 (xx) |
| PT (1) | PT1017408E (xx) |
| RU (1) | RU2201272C2 (xx) |
| TR (1) | TR199901853T2 (xx) |
| WO (1) | WO1998034630A1 (xx) |
| YU (1) | YU34199A (xx) |
| ZA (1) | ZA98753B (xx) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE292975T1 (de) * | 1997-02-05 | 2005-04-15 | Hoffmann La Roche | Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii |
| AR025609A1 (es) | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
| AR025587A1 (es) | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones en dispersion que contienen inhibidores de lipasa |
| DE60138333D1 (de) | 2000-03-14 | 2009-05-28 | Unilever Nv | Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen |
| US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US9174176B2 (en) | 2003-01-09 | 2015-11-03 | Disperse Systems, Inc. | Ultrasonic dispersion apparatus, system, and method |
| US7510849B2 (en) * | 2004-01-29 | 2009-03-31 | Glucolight Corporation | OCT based method for diagnosis and therapy |
| CA2580313C (en) | 2004-07-19 | 2016-03-15 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
| US7254429B2 (en) | 2004-08-11 | 2007-08-07 | Glucolight Corporation | Method and apparatus for monitoring glucose levels in a biological tissue |
| US8036727B2 (en) * | 2004-08-11 | 2011-10-11 | Glt Acquisition Corp. | Methods for noninvasively measuring analyte levels in a subject |
| JP2008537903A (ja) | 2005-04-13 | 2008-10-02 | グルコライト・コーポレーシヨン | Ｏｃｔが基になった血糖モニターのデータ処理および較正方法 |
| US8217025B2 (en) * | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
| EP2036575B1 (en) * | 2007-09-12 | 2010-08-18 | Mader S.r.l. | Pharmaceutical compositions for oral use for treating patients affected by obesity |
| MX2010004072A (es) * | 2007-10-15 | 2010-09-14 | Inventis Dds Pvt Ltd | Composicion farmaceutica de orlistat. |
| JP5868594B2 (ja) | 2007-10-16 | 2016-02-24 | バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ | 経口投与可能な固形医薬組成物及びそのプロセス |
| US8571617B2 (en) | 2008-03-04 | 2013-10-29 | Glt Acquisition Corp. | Flowometry in optical coherence tomography for analyte level estimation |
| US8309107B2 (en) * | 2008-10-06 | 2012-11-13 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
| FR3017536B1 (fr) * | 2014-02-18 | 2017-05-26 | Univ La Rochelle | Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase |
| JP2019515654A (ja) * | 2016-03-16 | 2019-06-13 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | 肥満及び／又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物 |
| US20190022061A1 (en) * | 2017-07-21 | 2019-01-24 | Kieu Hoang | Statins (Atorvastatin) can lower blood sugar level in diabetic |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1328881C (en) * | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA1270837A (en) * | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA2035972C (en) * | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
| US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
| US5345056A (en) * | 1991-12-12 | 1994-09-06 | Motorola, Inc. | Plasma based soldering by indirect heating |
| CA2098167C (en) * | 1992-06-24 | 2006-12-19 | Dorothea Isler | Foodstuffs and feedstuffs containing a lipase inhibitor |
| CA2128044C (en) * | 1993-08-05 | 2007-02-20 | Klaus-Dieter Bremer | Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor |
| JP3532999B2 (ja) * | 1995-03-24 | 2004-05-31 | 株式会社ロッテ | 新規なタンニン類およびこれを有効成分とするリパーゼ阻害剤 |
| JPH09227398A (ja) * | 1996-02-20 | 1997-09-02 | Zeria Pharmaceut Co Ltd | 抗肥満剤 |
| ATE292975T1 (de) * | 1997-02-05 | 2005-04-15 | Hoffmann La Roche | Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii |
| US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
-
1998
- 1998-01-29 AT AT98908008T patent/ATE292975T1/de active
- 1998-01-29 RU RU99118887/14A patent/RU2201272C2/ru active
- 1998-01-29 JP JP53371598A patent/JP2001509173A/ja active Pending
- 1998-01-29 NZ NZ336755A patent/NZ336755A/en not_active IP Right Cessation
- 1998-01-29 TR TR1999/01853T patent/TR199901853T2/xx unknown
- 1998-01-29 CN CNB988023245A patent/CN1154505C/zh not_active Expired - Lifetime
- 1998-01-29 CA CA2278854A patent/CA2278854C/en not_active Expired - Lifetime
- 1998-01-29 AU AU66169/98A patent/AU740375B2/en not_active Expired
- 1998-01-29 PL PL334975A patent/PL191222B1/pl unknown
- 1998-01-29 KR KR10-1999-7006983A patent/KR100479968B1/ko not_active IP Right Cessation
- 1998-01-29 ME MEP-903/08A patent/ME00578A/xx unknown
- 1998-01-29 IL IL13100798A patent/IL131007A0/xx not_active IP Right Cessation
- 1998-01-29 WO PCT/EP1998/000468 patent/WO1998034630A1/en active IP Right Grant
- 1998-01-29 ID IDW990792A patent/ID22650A/id unknown
- 1998-01-29 PT PT98908008T patent/PT1017408E/pt unknown
- 1998-01-29 DK DK98908008T patent/DK1017408T3/da active
- 1998-01-29 ES ES98908008T patent/ES2239799T3/es not_active Expired - Lifetime
- 1998-01-29 HU HU0001014A patent/HU230834B1/hu unknown
- 1998-01-29 EP EP98908008A patent/EP1017408B1/en not_active Revoked
- 1998-01-29 BR BR9807655-8A patent/BR9807655A/pt not_active Application Discontinuation
- 1998-01-29 DE DE69829763T patent/DE69829763T2/de not_active Expired - Lifetime
- 1998-01-29 CZ CZ19992651A patent/CZ295567B6/cs not_active IP Right Cessation
- 1998-01-29 YU YU34199A patent/YU34199A/sh unknown
- 1998-01-29 ZA ZA98753A patent/ZA98753B/xx unknown
- 1998-02-03 AR ARP980100471A patent/AR011106A1/es not_active Application Discontinuation
-
1999
- 1999-07-30 NO NO19993717A patent/NO324452B1/no not_active IP Right Cessation
- 1999-10-04 US US09/411,554 patent/US6147108A/en not_active Expired - Lifetime
-
2000
- 2000-07-21 HK HK00104500A patent/HK1025251A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO324452B1 (no) | Anvendelse av tetrahydrolipstatin til fremstilling av medikamenter mot diabetes | |
| IE66527B1 (en) | Bilobalide for use as a therapeutic substance | |
| Kamanyi et al. | Hypoglycaemic properties of the aqueous root extract of Morinda lucida (Benth)(Rubiaceae). Studies in the mouse | |
| JPH11503164A (ja) | 続発性上皮小体機能亢進症の治療のための薬剤の製造におけるビタミンｄ▲下２▼又はビタミンｄ▲下４▼誘導体の用途 | |
| CA2155009C (en) | Prevention and treatment of myocardial failure | |
| WO1995017889A1 (fr) | Composition therapeutique utile pour traiter l'hyperparathyroidie d'un patient en dialyse artificielle | |
| AU745759B2 (en) | Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration | |
| CA2877680A1 (en) | Use of 2-methylene-19-nor-(20s)-1.alpha., 25-dihydroxyvitamin d3 to treat secondary hyperparathyroidsm | |
| JPH05194209A (ja) | 血管内皮細胞機能改善剤 | |
| European Study Group | Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study) | |
| CN1777417B (zh) | PPARα激动剂和二甲双胍降低血清甘油三酯的用途 | |
| AU2002334001B2 (en) | Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia | |
| CN101757627A (zh) | 用于治疗糖尿病的联合用药及药物组合物 | |
| DE3035494A1 (de) | Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels | |
| RU2747985C1 (ru) | Твердофазная композиция для коррекции метаболических нарушений при сахарном диабете второго типа | |
| WO2002049636A1 (en) | An antidiabetic composition of amino acids | |
| CN1440287A (zh) | 治疗外周血管疾病、外周神经病和自主神经病的方法 | |
| JP3816545B2 (ja) | 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物 | |
| DE102017119313A1 (de) | Gallensäure enthaltendes appetitzügelndes Mittel | |
| MXPA99007163A (en) | Use of gastrointestinal lipase inhibitors | |
| WO2006111296A2 (de) | Darreichungsformen und kombinationsprärate von pyrimidinbiosyntheseinhibitoren zur erzielung zusätzlicher wirkungen auf das immunsystem | |
| SU1718948A1 (ru) | Способ лечени вирусного гепатита | |
| WO2021001464A1 (en) | Combination therapy methods, compositions and kits | |
| DE202017105073U1 (de) | Gallensäure enthaltendes appetitzügelndes Mittel | |
| CN106880643A (zh) | 用于治疗糖尿病的联合用药及药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |